Genzyme Corporation

10 Jun 2011 • by Natalie Aster

Genzyme’s recent well-documented contamination issues at its primary manufacturing site at Allston, MA, has significantly impacted the company’s top-line prescription pharmaceutical sale performance over the period 2008–10. Prior to this, Genzyme’s total pharmaceutical sales were increasing at double-digit year-on-year growth rates. With the temporary shutdown of the Allston during 2009, followed by the loss in inventory levels of its leading lysosomal storage disorders (LDSs) therapies Cerezyme and Fabrazyme, Genzyme has seen a contraction in its total prescription pharmaceuticals sales of -$149m. In 2010, Genzyme reported total sales of $4,048m, a small decline on the reported figure for 2009.

The analysis “Genzyme Corporation” by Datamonitor examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Despite the blip through 2008–10, over the forecast period Genzyme’s total prescription pharmaceuticals are forecast to recover and increase at a 9.4% CAGR over 2010–16. The company’s LSDs therapies will be the driver for this growth, in particular Myozyme/Lumizyme. In addition, Genzyme’s strategy of diversifying its therapy area offering will pay off out to 2016, with considerable growth expected from its expanding interest in the therapy areas of oncology and cardiovascular.

Report Details:

Genzyme Corporation

Published: May 2011

Pages: 95

Price: US$ 5,700

Report Sample Abstract

Traditionally US-based biotechnology firms garner the majority of their sales from their domestic markets, however, given the epidemiologic spread of Genzyme’s core therapeutic interest (rare genetic disorders) the company boasts a wide reaching presence in the market. In 2010 Genzyme derived half of its total prescription pharma sales from the US, with the 5EU contributing a significant 31.9%. The RoW was the company’s third largest contributor to sales in 2010, with 13.7% of total 2010 revenues derived from this geographic region, with Genzyme reporting a very small presence in Japan (3.7% of 2010 sales).

Over the forecast period Genzyme will continue to generate the majority of its sales from the US market, with the cost of its ultra-specialist therapies a major factor in this US-centered growth. However, despite this, Genzyme is forecast to derive sales growth from the more cost conscious 5EU and RoW markets. The US market is forecast to generate 53.2% of Genzyme’s total forecast absolute growth, with the RoW predicted to contribute 20.5%, and the 5EU forecast to provide 19.5%.

More information can be found in the report “Genzyme Corporation” by Datamonitor.

To order the report or ask for sample pages contact



MarketPublishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970